159 related articles for article (PubMed ID: 17310323)
21. Selective monitoring of the enzymatic activity of the tumor suppressor Fhit.
Hacker SM; Mortensen F; Scheffner M; Marx A
Angew Chem Int Ed Engl; 2014 Sep; 53(38):10247-50. PubMed ID: 25098403
[TBL] [Abstract][Full Text] [Related]
22. Correlation of intracellular diadenosine triphosphate (Ap3A) with apoptosis in Fhit-positive HEK293 cells.
Fisher DI; McLennan AG
Cancer Lett; 2008 Feb; 259(2):186-91. PubMed ID: 18006149
[TBL] [Abstract][Full Text] [Related]
23. Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells.
Yutori H; Semba S; Komori T; Yokozaki H
Cancer Sci; 2008 Mar; 99(3):524-30. PubMed ID: 18167129
[TBL] [Abstract][Full Text] [Related]
24. Two hydrolase resistant analogues of diadenosine 5',5"'-P1,P3-triphosphate for studies with Fhit, the human fragile histidine triad protein.
Blackburn GM; Liu X; Rösler A; Brenner C
Nucleosides Nucleotides; 1998; 17(1-3):301-8. PubMed ID: 9708352
[TBL] [Abstract][Full Text] [Related]
25. Selective degradation of 2'-adenylated diadenosine tri- and tetraphosphates, Ap(3)A and Ap(4)A, by two specific human dinucleoside polyphosphate hydrolases.
Guranowski A; Galbas M; Hartmann R; Justesen J
Arch Biochem Biophys; 2000 Jan; 373(1):218-24. PubMed ID: 10620341
[TBL] [Abstract][Full Text] [Related]
26. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.
Weiske J; Albring KF; Huber O
Proc Natl Acad Sci U S A; 2007 Dec; 104(51):20344-9. PubMed ID: 18077326
[TBL] [Abstract][Full Text] [Related]
27. TRAIL-induced apoptosis of FHIT-negative lung cancer cells is inhibited by FHIT re-expression.
Mirandola P; Gobbi G; Sponzilli I; Malinverno C; Cavazzoni A; Alfieri R; Petronini PG; Vitale M
J Cell Physiol; 2009 Aug; 220(2):492-8. PubMed ID: 19418484
[TBL] [Abstract][Full Text] [Related]
28. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions.
Pichiorri F; Okumura H; Nakamura T; Garrison PN; Gasparini P; Suh SS; Druck T; McCorkell KA; Barnes LD; Croce CM; Huebner K
J Biol Chem; 2009 Jan; 284(2):1040-9. PubMed ID: 19004824
[TBL] [Abstract][Full Text] [Related]
29. In vitro inhibition of the enzymatic activity of tumor suppressor FHIT gene product by carcinogenic transition metals.
Kowara R; Karaczyn AA; Fivash MJ; Kasprzak KS
Chem Res Toxicol; 2002 Mar; 15(3):319-25. PubMed ID: 11896678
[TBL] [Abstract][Full Text] [Related]
30. [FHIT--tumor suppressor protein involved in induction of apoptosis and cell cycle regulation].
Pecherzewska R; Nawrot B
Postepy Biochem; 2009; 55(1):66-75. PubMed ID: 19514467
[TBL] [Abstract][Full Text] [Related]
31. Fluorimetric detection of enzymatic activity associated with the human tumor suppressor Fhit protein.
Asensio AC; Oaknin S; Rotllán P
Biochim Biophys Acta; 1999 Jul; 1432(2):396-400. PubMed ID: 10407161
[TBL] [Abstract][Full Text] [Related]
32. Replacement of Fhit in cancer cells suppresses tumorigenicity.
Siprashvili Z; Sozzi G; Barnes LD; McCue P; Robinson AK; Eryomin V; Sard L; Tagliabue E; Greco A; Fusetti L; Schwartz G; Pierotti MA; Croce CM; Huebner K
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13771-6. PubMed ID: 9391102
[TBL] [Abstract][Full Text] [Related]
33. Restoration of fragile histidine triad (FHIT) expression inhibits cell growth and induces apoptosis in cutaneous T-cell lymphoma cell line.
Song X; Tian Z; Wang S; Peng Z; Feng J
Cancer Invest; 2010 Dec; 28(10):1019-23. PubMed ID: 20690795
[TBL] [Abstract][Full Text] [Related]
34. Distribution of Fhit protein in rat tissues and its intracellular localization.
Golebiowski F; Kowara R; Pawelczyk T
Mol Cell Biochem; 2001 Oct; 226(1-2):49-55. PubMed ID: 11768238
[TBL] [Abstract][Full Text] [Related]
35. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
36. Aberrant FHIT protein expression in classical Hodgkin's lymphoma: a potential marker.
Zhao P; Lam AK; Lu YL; Zhong M; Chen LH; Pu XL
Pathology; 2006 Oct; 38(5):399-402. PubMed ID: 17008276
[TBL] [Abstract][Full Text] [Related]
37. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
[TBL] [Abstract][Full Text] [Related]
38. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
Semba S; Trapasso F; Fabbri M; McCorkell KA; Volinia S; Druck T; Iliopoulos D; Pekarsky Y; Ishii H; Garrison PN; Barnes LD; Croce CM; Huebner K
Oncogene; 2006 May; 25(20):2860-72. PubMed ID: 16407838
[TBL] [Abstract][Full Text] [Related]
39. Stereochemical retention of the configuration in the action of Fhit on phosphorus-chiral substrates.
Abend A; Garrison PN; Barnes LD; Frey PA
Biochemistry; 1999 Mar; 38(12):3668-76. PubMed ID: 10090754
[TBL] [Abstract][Full Text] [Related]
40. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
